JP7023371B2 - 胆汁うっ滞性そう痒の処置 - Google Patents

胆汁うっ滞性そう痒の処置 Download PDF

Info

Publication number
JP7023371B2
JP7023371B2 JP2020538758A JP2020538758A JP7023371B2 JP 7023371 B2 JP7023371 B2 JP 7023371B2 JP 2020538758 A JP2020538758 A JP 2020538758A JP 2020538758 A JP2020538758 A JP 2020538758A JP 7023371 B2 JP7023371 B2 JP 7023371B2
Authority
JP
Japan
Prior art keywords
cholestasis
agent according
ceradelpal
pruritus
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020538758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535225A (ja
JP2020535225A5 (enExample
Inventor
ポル・ブーズ
チャールズ・エイ・マックウェーター
アレクサンドラ・エス・スタインバーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Publication of JP2020535225A publication Critical patent/JP2020535225A/ja
Publication of JP2020535225A5 publication Critical patent/JP2020535225A5/ja
Application granted granted Critical
Publication of JP7023371B2 publication Critical patent/JP7023371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ladders (AREA)
JP2020538758A 2017-09-26 2018-09-24 胆汁うっ滞性そう痒の処置 Active JP7023371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26
US62/563,395 2017-09-26
PCT/US2018/052490 WO2019067373A1 (en) 2017-09-26 2018-09-24 TREATMENT OF CHOLESTATIC PRURIT

Publications (3)

Publication Number Publication Date
JP2020535225A JP2020535225A (ja) 2020-12-03
JP2020535225A5 JP2020535225A5 (enExample) 2021-11-04
JP7023371B2 true JP7023371B2 (ja) 2022-02-21

Family

ID=64564950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020538758A Active JP7023371B2 (ja) 2017-09-26 2018-09-24 胆汁うっ滞性そう痒の処置

Country Status (26)

Country Link
US (2) US20190105291A1 (enExample)
EP (3) EP3973959B8 (enExample)
JP (1) JP7023371B2 (enExample)
KR (1) KR102376794B1 (enExample)
CN (1) CN111132675B (enExample)
AU (2) AU2018342323B2 (enExample)
BR (1) BR112020005074A2 (enExample)
CA (1) CA3076614C (enExample)
CY (1) CY1124894T1 (enExample)
DK (1) DK3973959T3 (enExample)
ES (2) ES3012120T3 (enExample)
FI (1) FI3973959T3 (enExample)
HR (2) HRP20250022T1 (enExample)
HU (2) HUE057377T2 (enExample)
IL (2) IL273569B (enExample)
LT (2) LT3973959T (enExample)
MX (1) MX392537B (enExample)
PL (2) PL3687523T3 (enExample)
PT (2) PT3973959T (enExample)
RS (1) RS62790B1 (enExample)
SG (1) SG11202002253SA (enExample)
SI (2) SI3687523T1 (enExample)
SM (1) SMT202200171T1 (enExample)
UA (1) UA125600C2 (enExample)
WO (1) WO2019067373A1 (enExample)
ZA (1) ZA202001646B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20220140762A (ko) * 2020-02-10 2022-10-18 장피트 엘라피브라노에 의한 원발 담즙성 담관염의 치료
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
HUE066653T2 (hu) 2021-02-01 2024-08-28 Cymabay Therapeutics Inc Cholangiopathiák kezelése seladelparral
EP4654957A1 (en) 2023-01-29 2025-12-03 CymaBay Therapeutics, Inc. Treatment of uremic pruritus
KR20250139304A (ko) 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508817A (ja) 2014-03-20 2017-03-30 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. 肝内胆汁うっ滞症の治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508817A (ja) 2014-03-20 2017-03-30 サイマベイ・セラピューティクス・インコーポレイテッドCymaBay Therapeutics,Inc. 肝内胆汁うっ滞症の治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEPATOLOGY,2014年,Vol. 60, No. 1,pp.399-407
JONES, D. et al.,LB-9, A phase 2 proof concept study of MBX-8025 in patients with Primary Biliary Cholangitis (PBC) who are inadequate responders to ursodeoxycholic acid (UDCA),HEPATOLOGY,2016年12月,Vol.64, No.6(Suppl.),pp.1123A-1124A

Also Published As

Publication number Publication date
CY1124894T1 (el) 2023-01-05
ES3012120T3 (en) 2025-04-08
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (enExample) 2022-02-14
CN111132675B (zh) 2023-04-25
EP3973959A1 (en) 2022-03-30
EP3973959B1 (en) 2024-12-11
US20210283078A1 (en) 2021-09-16
JP2020535225A (ja) 2020-12-03
LT3687523T (lt) 2022-03-25
IL288340A (en) 2022-01-01
ZA202001646B (en) 2021-08-25
US20190105291A1 (en) 2019-04-11
PT3687523T (pt) 2021-12-06
SI3973959T1 (sl) 2025-03-31
WO2019067373A1 (en) 2019-04-04
IL288340B1 (en) 2023-01-01
EP3973959B8 (en) 2025-01-15
KR20200058458A (ko) 2020-05-27
HUE057377T2 (hu) 2022-05-28
RU2020114644A (ru) 2021-10-27
IL273569B (en) 2021-12-01
SI3687523T1 (sl) 2022-05-31
PL3973959T3 (pl) 2025-03-24
CA3076614A1 (en) 2019-04-04
BR112020005074A2 (pt) 2020-09-15
AU2021254641B2 (en) 2022-02-24
LT3973959T (lt) 2025-01-10
AU2021254641A1 (en) 2021-11-18
CA3076614C (en) 2023-02-07
UA125600C2 (uk) 2022-04-27
IL288340B2 (en) 2023-05-01
IL273569A (en) 2020-05-31
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
EP3687523A1 (en) 2020-08-05
MX2020007273A (es) 2022-05-23
MX392537B (es) 2025-03-04
PL3687523T3 (pl) 2022-02-21
AU2018342323A1 (en) 2020-04-16
SMT202200171T1 (it) 2022-05-12
PT3973959T (pt) 2025-01-24
EP3687523B1 (en) 2021-11-03
AU2018342323B2 (en) 2021-09-23
NZ762976A (en) 2021-11-26
HRP20212010T1 (hr) 2022-04-01
EP4523744A3 (en) 2025-06-04
RS62790B1 (sr) 2022-02-28
FI3973959T3 (fi) 2025-02-03
CN111132675A (zh) 2020-05-08
SG11202002253SA (en) 2020-04-29
HUE070033T2 (hu) 2025-05-28
ES2902349T3 (es) 2022-03-28
DK3973959T3 (da) 2025-01-20

Similar Documents

Publication Publication Date Title
JP7023371B2 (ja) 胆汁うっ滞性そう痒の処置
JP6568577B2 (ja) 肝内胆汁うっ滞症の治療
JP7079735B2 (ja) 肝内胆汁うっ滞性疾患の処置
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
RU2781281C2 (ru) Лечение холестатического зуда
HK40121699A (en) Treatment of cholestatic pruritus
HK40062783B (en) Treatment of cholestatic pruritus with seladelpar
HK40062783A (en) Treatment of cholestatic pruritus with seladelpar
HK40033446B (en) Treatment of cholestatic pruritus with seladelpar
HK40033446A (en) Treatment of cholestatic pruritus with seladelpar
NZ762976B2 (en) Treatment of cholestatic pruritus
JP7596548B2 (ja) 胆管症の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210921

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220208

R150 Certificate of patent or registration of utility model

Ref document number: 7023371

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250